Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Low-Dose semaglutide: a new hope for weight loss in obese adults?

NCT ID NCT07513168

Disease control Sponsor: Asian Institute Of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is testing a low-dose version of the drug semaglutide to help obese adults lose weight and improve heart health. The trial includes 60 Pakistani adults who are obese but do not have diabetes. Participants will receive weekly injections for 24 weeks, along with diet and exercise advice. The goal is to see if this lower dose is both safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (low-dose)
What this could lead to
If successful, this could provide a safe, low-dose option for weight loss and improved heart health in obese adults without diabetes.
What could go wrong
This is a small, early-phase trial with no placebo group, so results may not be definitive. Side effects like nausea or pancreatitis are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Body mass index (BMI ≥ 27.5 kg/m²) according to WHO Asian cut-offs. * No diagnosis of type 2 diabetes mellitus, confirmed by: Fasting blood glucose \< 126 mg/dL, and HbA1c \< 6.5% within three months prior to enrollment. * Willingness and ability to provide written informed consent. * Willingness to comply with study procedures, including weekly injections and lifestyle counseling. Exclusion Criteria: * History of pancreatitis. * History or presence of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2). * Pregnant or lactating women. * Severe renal impairment (eGFR \< 30 mL/min/1.73 m²) or hepatic impairment (ALT or AST \> 3× upper limit of normal). * Current use of other anti-obesity medications. * Known hypersensitivity to semaglutide or any component of the formulation. * Any condition that, in the investigator's opinion, would interfere with participation, adherence, or safety in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiometabolic risk factors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiometabolic risk factors Obesity Weight reduction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Asian Institute of Medical Sciences

    RECRUITING

    Hyderābād, Sindh, 71000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.